Last update Jan. 15, 2020
Very Low Risk
An antiprotozoal and antibacterial (anaerobic bacteria). Indicated in urogenital trichomoniasis, non-specific vaginitis, giardiasis, intestinal and hepatic amebiasis, acute ulcerative gingivitis and prophylaxis of postoperative infections by anaerobic bacteria.
Administered orally or intravenously in a single or daily dose for 3 to 6 days according to pathology.
It is excreted in breastmilk in clinically insignificant amounts (Evaldson 1985, Männistö 1983, Wood 1982), much lower than the dose prescribed to infants.
Its use is authorized in infants from one month old.
Some authors recommend waiting 3 days before breastfeeding again following administration (CDC 2010, Evaldson 1985). In the meantime, express and discard breastmilk regularly.
The possibility of transient gastroenteritis due to altered intestinal flora in infants whose mothers take antibiotics should be taken into account (Ito 1993).
It has very little plasma absorption when used topically, as a cream or vaginal ovules, so the amount excreted in milk is expected to be even less than following systemic administration.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM